How can gene-editing technology raise questions about unequal access to medical treatments?

Gene-editing technology, such as CRISPR, raises significant concerns regarding equitable access to medical treatments. While these tools offer transformative potential for addressing human disease, several factors contribute to disparities in who can benefit from them:

• High Costs and Resource Intensity: Advanced gene-editing therapies, such as the FDA-approved treatment Casgevy, are extremely costly and often require complex, intensive medical procedures. These financial and logistical barriers can make such treatments inaccessible to patients without adequate health insurance or to those living in regions with limited medical resources.12
• Ethical Debates on Enhancement: The ability to edit genes has sparked concerns that the technology could be used to improve non-medical traits, such as intelligence or physical appearance. This raises profound ethical questions about who would have the financial means to access these "designer" enhancements, potentially exacerbating existing social inequalities.134
• Research Representation: Similar to broader challenges in personalized medicine, there is a risk that the development of these technologies may be biased if research primarily focuses on specific populations. If genetic data and clinical trials underrepresent diverse ethnic and racial groups, the resulting therapies may be less effective or less safe for those excluded from the research process.2

Ensuring that these powerful tools are used ethically and equitably remains a critical challenge for the global scientific and medical community.14